Rebecca S Heist

15PUBLICATIONS
210CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Nov 10, 2026
Prevalence and Actionability of MTAP Loss in Driver Oncogene-Positive and Oncogene-Negative Lung Cancer.

|Feb 06, 2026
Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.

Takashi Sakai, Zofia Piotrowska, Charlotte I Wang

|Jan 06, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.

Jacob Sands, Myung-Ju Ahn, Aaron Lisberg

|Oct 29, 2024
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.

Catherine B Meador, Subba R Digumarthy, Beow Y Yeap

|Apr 02, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti

|Mar 08, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.

Ryan B Corcoran, Khanh T Do, Jeong E Kim

Pageof 3

Frequent Collaborators

4 joint publications

Mari Mino-Kenudson

4 joint publications

Ibiayi Dagogo-Jack

3 joint publications

Beow Y Yeap

3 joint publications

Alexander Spira